SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Intel Corp. engages in the design, manufacture, and sale of computer products and technologies. It delivers computer, networking, data storage, and communications platforms. The firm operates through the following segments: Client Computing Group (CCG), Data Center and AI (DCAI), Network and Edge (NEX), Mobileye, Accelerated Computing Systems and Graphics (AXG), Intel Foundry Services (IFS), and All Other. The CCG segment consists of platforms designed for notebooks, 2-in-1 systems, desktops, tablets, phones, wireless and wired connectivity products, and mobile communication components. The DCAI segment delivers solutions to cloud service providers and enterprise customers, along with silicon devices for communications service providers and high-performance computing customers. The NEX segment offers computing system solutions from inflexible fixed-function hardware to general-purpose compute, acceleration, and networking devices running cloud native software on programmable hardware. The Mobileye segment develops driving assistance and self-driving solutions. The AXG segment provides products and technologies designed to help customers solve the toughest computational problems. Its products include CPUs for high-performance computing and GPUs targeted for a range of workloads and platforms, from gaming and content creation on client devices to delivering media and gaming in the cloud, and the most demanding high-performance computing and AI workloads on supercomputers. The IFS segment refers to full stack solutions created from the foundry industry ecosystem. The All Other segment represents results from other non-reportable segments and corporate-related charges. The company was founded by Robert Norton Noyce and Gordon Earle Moore on July 18, 1968 and is headquartered in Santa Clara, CA.

Intel Corp.

Intel Corp

Intel is trending following news of a significant investment and partnership with Nvidia, driving optimism about its future in AI and data centers. Community discussions revolve around the potential impact on Intel's competitive position, particularly against AMD, and the strategic implications of Nvidia's move. Some investors express concerns about Intel's existing debt and the details of the partnership, while others see it as a major step in the right direction for the company.

A project grown out of the community's love and passion for the weed culture. Launched around early 2025, $weedcoin, “Like Bitcoin but way higher,” emphasizes its alignment with cannabis culture and a laid-back vibe. Unlike other Weed communities, this project leans heavily into community engagement over technical utility, aiming to build a “stoner community” through social media presence and decentralized governance. We also aim to focus on onboarding web2 businesses and users onto web3 through the token.

Weedcoin

Weedcoin is trending as community members rally around the crypto's focus on cannabis culture and positivity, emphasizing its unique position in the Web3 space. Discussions highlight the coin's connection to a large cultural movement and its potential for growth. The community emphasizes $WEEDCOIN.X represents a culture, not just a coin.

Tesla, Inc. engages in the design, development, manufacture, and sale of electric vehicles and energy generation and storage systems. It operates through the Automotive and Energy Generation and Storage segments. The Automotive segment includes the design, development, manufacture, sale, and lease of electric vehicles as well as sales of automotive regulatory credits. The Energy Generation and Storage segment is involved in the design, manufacture, installation, sale, and lease of solar energy generation, energy storage products, and related services and sales of solar energy systems incentives. The company was founded by Jeffrey B. Straubel, Elon Reeve Musk, Martin Eberhard, and Marc Tarpenning on July 1, 2003 and is headquartered in Austin, TX.

Tesla Inc

Tesla is trending amidst a mix of factors including analyst upgrades with high price targets based on AI leadership, countered by criticism regarding recent project setbacks. Community discussions revolve around potential price movements, key technical levels like $440, and reactions to news like executive departures and potential impacts from US-India trade relations. Investors are weighing bullish analyst perspectives against concerns about valuation, competition, and regulatory scrutiny.

Brera Holdings Plc engages in the business of football division progression, global football player transfer service, sponsorship services, football school services, and consulting services on football projects. The company was founded on June 30, 2022 and is headquartered in Dublin, Ireland.

Brera Holdings PLC - Ordinary Shares - Class B

Brera Holdings PLC

BREA is trending following news of a $300M Solana treasury initiative, generating significant buzz around its potential in the digital asset space. The community is discussing the involvement of ARK Invest and the company's rebranding as Solmate, with some anticipating a continued run while others express skepticism about its long-term value. Speculation about a short squeeze is rampant due to the stock's low float.

"Shina Inu is a decentralized meme token on the Ethereum blockchain. Its mission is to give back to the crypto community, give to charity, and win the heart of the greatest token of all time, Shiba Inu!   Shina Token is a very fun meme token project that has sold many rare and beautiful NFTs. NFT sales are used to support the team and provide upcoming features such as exclusive access to events and rewards that will soon be announced."

Shina Inu

Shina Inu is trending as community members highlight its bullish chart setup, potential breakout, and strong accumulation patterns. Discussions revolve around the building momentum and anticipation for a significant move, with some suggesting whales are accumulating positions. The community emphasizes the organic growth and potential for SHI to trend strongly.

The Trade Desk, Inc. engages in the provision of a self-service and cloud-based ad-buying platform. It operates through the United States and International geographical segments. The firm offers omnichannel advertising, audience targeting, solutions for identity, application programming interface (API), custom, and programmatic, measurement and optimization. The company was founded by Jeffrey Terry Green and David Pickles in November 2009 and is headquartered in Ventura, CA.

Trade Desk Inc - Ordinary Shares - Class A

Trade Desk Inc

Trade Desk is trending as the stock has continued to decline, prompting discussions on whether it's oversold or a value trap, with some investors seeing it as a buying opportunity while others express concerns about competition from walled gardens and recent analyst downgrades. The community is closely watching for a potential reversal, analyzing support and resistance levels, and awaiting any news or actions from management that could shift the stock's trajectory. Some are attributing the continued decline to market manipulation and negative articles.

BrokeCoin is a meme-meets-utility cryptocurrency project operating under the ethos of Transparency, Community, and Respect. Formally registered as an LLC in Wyoming, USA, BrokeCoin is building an expansive ecosystem that combines light-hearted spirit of meme culture with real-world crypto utilities—spanning gaming, staking, NFTs, web services, and an e-commerce platform. Brokecoin believes in developing useful and interesting meme-inspired utilities to both service the crypto industry, and generate value for holders.

Brokecoin

Brokecoin is trending as the community rallies around upcoming catalysts, including a potential listing on Bifinance and a locked airdrop for holders. Talk centers on buying the dip, with community members highlighting the project's longevity and developer engagement in the Solana meme space. The community is also anticipating a token burn upon reaching 2000 watchers.

AlphaVest Acquisition Corp. is a blank check company, which engages in effecting a merger, stock exchange, asset acquisition, stock purchase, and reorganization or similar business combination. The company was founded on January 14, 2022 and is headquartered in New York, NY.

AlphaVest Acquisition Corp

ATMV is trending due to significant price volatility, triggering multiple trading halts. The community is actively discussing the stock's low float and potential merger agreement, with some speculating about a potential short squeeze. Recent SEC filings and news regarding an adjourned shareholder meeting are also circulating.

Literally a dog wif a hat, dogwifhat (WIF) is a meme coin that's part of the ever-growing ecosystem of digital currencies on the Solana blockchain. This token brings a lighthearted twist to cryptocurrency, featuring a playful dog with a hat as its mascot, symbolising a more whimsical approach to the often serious domain of digital finance.

dogwifhat

Dogwifhat (WIF.X) is gaining attention as traders discuss its potential to break past resistance levels and reach new highs, with some pointing to a cup and handle formation. Community members are actively debating entry and exit points, while closely monitoring Bitcoin's dominance and its impact on altcoins. Speculation around potential price targets and the influence of market makers is contributing to the heightened interest in this meme coin.

"What's Updog?" is a Community Led token.

UpDog

UpDog is trending as community members actively promote the Solana-based memecoin and playfully ask, "What's Updog?" driving engagement and curiosity. The project, which has been around for over a year, is known for its Jupiter Strict List status and its joke-driven meme culture, with community members expressing bullish sentiment. The community is also highlighting the project's focus on charitable donations, aiming to stand out in the crowded memecoin space.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Cadrenal Therapeutics, Inc. (CVKD) on Monday announced the acquisition of new assets from eXIthera Pharmaceuticals.The company <a target="_blank" rel="noopener noreferrer nofollow" href="https://www.globenewswire.com/news-release/2025/09/15/3149938/0/en/Cadrenal-Therapeutics-Enhances-Anticoagulation-Pipeline-Through-Acquisition-of-eXIthera-s-Portfolio-of-Factor-XIa-Inhibitors.html">said</a> that the acquisition will significantly enhance its pipeline by adding novel assets in acute and chronic anticoagulation settings. As per the deal, eXIthera will receive milestone payments from Cadrenal totaling up to $15 million, subject to the realization of certain future clinical and regulatory milestones. eXIthera will also be entitled to royalties on global sales of the acquired assets upon future commercialization.CVKD shares jumped 2% at the time of writing. On Stocktwits, retail sentiment around <a href="https://stocktwits.com/symbol/CVKD">CVKD stock</a> fell from ‘bullish’ to ‘neutral’ territory over the past 24 hours, while message volume stayed at ‘low’ levels.The deal includes eXIthera’s portfolio of investigational intravenous (IV) and oral Factor XIa inhibitors, a new class of anticoagulants. This includes eXIthera’s lead asset, Frunexian, being studied for acute anticoagulation, EP-7327, an oral small molecule candidate for chronic indications, and an extensive portfolio of additional small molecules.“With this acquisition, Cadrenal is the only company in the world developing a novel vitamin K antagonist (tecarfarin) and Factor XIa inhibitors, a promising new class of anticoagulants,” said Cadrenal CEO Quang X. Pham.“With tecarfarin planning a trial in patients with end-stage kidney disease transitioning to dialysis, our plans for LVAD patients, and the current addition of frunexian and EP-7327, we believe that Cadrenal is strategically positioned to deliver differentiated therapeutics across the entire spectrum of patients with cardiovascular thrombotic risk,” he added.Sichuan Haisco Pharmaceuticals retains rights to Frunexian in China under a pre-existing license agreement, the company said. Cadrenal will, however, be entitled to receive royalties of Frunexian sales in China.CVKD stock is down 8% this year but up approximately 20% over the past 12 months.Read also: <a href="https://stocktwits.com/news-articles/markets/equity/trump-fed-rate-cut-this-week-too-late-powell-bigger-than-he-had-in-mind/chwwONNRdUh">Trump Says ‘Too Late’ Powell Must Cut Rates Now, And ‘Bigger Than He Had In Mind’ Ahead Of Fed Meeting This Week</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Global stock market chart and trading board - stock photo

Cadrenal Therapeutics Expands Pipeline With Portfolio Acquisition Worth Up To $15 Million

The company said that the acquisition will significantly enhance its pipeline by adding novel assets in acute and chronic anticoagulation settings.

Equity

Cadrenal Therapeutics Announces Chief Medical Officer Transition to Advance Clinical Development of Tecarfarin

Cadrenal Therapeutics, Inc. (Nasdaq: CVKD), a late-stage biopharmaceutical company focused on the development of specialized cardiovascular therapies, with the late-stage asset tecarfarin, a new...

Cadrenal Therapeutics to Present at BIO CEO & Investor Conference

Cadrenal Therapeutics, Inc. (Nasdaq: CVKD), a late-stage biopharmaceutical company focused on the development of specialized cardiovascular therapies, leading with tecarfarin, a new Vitamin K...

Cadrenal Therapeutics to Participate in the Lytham Partners 2025 Investor Healthcare Summit on January 13, 2025

Cadrenal Therapeutics, Inc., (Nasdaq: CVKD), today announced that Chairman and Chief Executive Officer, Quang X. Pham, will participate in a webcasted fireside chat at the Lytham Partners 2025...

Cadrenal Therapeutics Provides 2024 Year-End Company Update, Reinforcing Clinical Development Plan for Tecarfarin in LVAD and Other Rare Cardiovascular Indications

Cadrenal Therapeutics, Inc. (Nasdaq: CVKD) today recapped its 2024 milestones and highlighted a clear path forward to develop the investigational drug tecarfarin as a superior and safer chronic...

Cadrenal Therapeutics Gears Up for the 43rd Annual J.P. Morgan Healthcare Conference Week with Event Participation and Investor/Partner Meetings

Cadrenal Therapeutics, Inc. (Nasdaq: CVKD), announced today its engagement in three key events leading up to and during the 43rd Annual J.P. Morgan Healthcare Conference Week, to be held on January...

Cadrenal Therapeutics Named Anticoagulation Therapy Company of the Year by Pharma Tech Outlook

Cadrenal Therapeutics Named Anticoagulation Therapy Company of the Year by Pharma Tech Outlook Cadrenal Therapeutics Named Anticoagulation Therapy Company of the Year by Pharma Tech Outlook PR...

CADRENAL THERAPEUTICS PROVIDES THIRD-QUARTER CORPORATE UPDATE

CADRENAL THERAPEUTICS PROVIDES THIRD-QUARTER CORPORATE UPDATE CADRENAL THERAPEUTICS PROVIDES THIRD-QUARTER CORPORATE UPDATE PR Newswire PONTE VEDRA, Fla., Nov. 7, 2024 PONTE VEDRA, Fla., Nov. 7, 2024...

Cadrenal Therapeutics Announces Exercise of Warrants for $4.7 Million Gross Proceeds

Cadrenal Therapeutics Announces Exercise of Warrants for $4.7 Million Gross Proceeds Cadrenal Therapeutics Announces Exercise of Warrants for $4.7 Million Gross Proceeds PR Newswire PONTE VEDRA...

Cadrenal Therapeutics Raises $5.1 Million via At-The-Market Facility

Cadrenal Therapeutics Raises $5.1 Million via At-The-Market Facility Cadrenal Therapeutics Raises $5.1 Million via At-The-Market Facility PR Newswire PONTE VEDRA, Fla., Oct. 24, 2024 PONTE VEDRA...

Cadrenal Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in developing novel therapy. It develops tecarfarin, a novel therapy with orphan drug indication, designed for the prevention of systemic thromboembolism of cardiac origin in patients with end-stage renal disease and atrial fibrillation. The company was founded by Quang X. Pham and Matthew K. Szot on January 25, 2022 and is headquartered in Ponte Vedra, FL.

Cadrenal Therapeutics Inc

Just the one

Three

Four

The Fed just cut rates. How many cuts do you expect in all of 2025? 
 
*Powered by Polymarket

CVKD
Cadrenal Therapeutics, Inc.

Feed

News

Sentiment

Fundamentals

Info

Poll

Latest CVKD News

CVKD Cadrenal Therapeutics, Inc.